Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
Intra-Cellular Therapies (ITCI) Stock Price & Analysis
711 Followers
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$42.01 - $66.00
Previous Close$45.96
Volume428.21K
Average Volume (3M)687.21K
Market Cap
$4.41B
Enterprise Value$3.81B
Total Cash (Recent Filing)$591.90M
Total Debt (Recent Filing)$20.04M
Price to Earnings (P/E)-16.8
Beta0.26
Next Earnings
May 10, 2023EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding94,705,054
10 Day Avg. Volume676,672
30 Day Avg. Volume687,213
Standard Deviation0.36
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)6.91
Price to Sales (P/S)29.29
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-20.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.28
Enterprise Value/Gross Profit16.65
Enterprise Value/Ebitda-14.48
Forecast
1Y Price Target
$72.00Price Target Upside55.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Intra-Cellular Therapies News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $42.01 and its highest was $66.00 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is May 10, 2023 which is in 50 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on Mar 01, 2023. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.592 by $0.142.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.62.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 95,280,010 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.592. Following the earnings report the stock price went up 0.591%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Woodline Partners LP. It holds Intra-Cellular Therapies’s shares valued at 21M.
---
Intra-Cellular Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.00 (55.49% Upside)
$72.00 (55.49% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 61.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $254.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.71%
12-Months-Change
Fundamentals
Return on Equity
-47.72%
Trailing 12-Months
Asset Growth
54.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
---